Ototoxicity of cisplatin in gynaecological cancer patients.
The ototoxic side effect of a moderate dose of cisplatin was studied by regular audiometric investigations in 186 women with gynaecologic cancer. Cisplatin was given in a dose of 50 mg/m2 body surface by intravenous infusion every 4 weeks. High-frequency hearing loss occurred in 40 patients (22%), but in no single case was a significant change observed in the frequency range of 0.5-2 kHz. Older patients showed a statistically significant greater incidence of audiometric changes, but the pretreatment audiogram was not a predictor for ototoxic changes. It is concluded that a moderate dose of cisplatin does not effect the ability to communicate.
Laurell
G
G
Department of Physiology, Karolinska Institute, Stockholm, Sweden.
Borg
E
E
D000328:Adult; D000368:Aged; D001301:Audiometry, Pure-Tone; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D034381:Hearing Loss / Q000139:chemically induced*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced*; D006801:Humans; D008875:Middle Aged; D011304:Presbycusis / Q000150:complications
D002945:Cisplatin